Evaluation of 5‐year imatinib treatment of 458 patients with <scp>CP</scp>‐<scp>CML</scp> in routine clinical practice and prognostic impact of different <scp>BCR</scp>‐<scp>ABL</scp> cutoff levels
Cancer medicine